- Mechanism
- Activates AMPK to stimulate fat oxidation
- Typical research dose
- 10-50 mg/kg/day (murine models)
- Route
- subcutaneous, intravenous
- Half-life
- 1-2 hours (intravenous)
- Legal status
- Research Only / WADA Prohibited
Overview
AICAR (5-Aminoimidazole-4-carboxamide Ribonucleotide), also known as Acadesine, is a synthetic small molecule widely researched as an exercise mimetic. It functions primarily by activating AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. By tricking the body into a state of perceived energy depletion, the AICAR peptide stimulates fat oxidation, enhances mitochondrial biogenesis, and improves endurance without physical exertion. This makes it a highly compelling subject in metabolic research, particularly for conditions like obesity, diabetes, and muscle wasting.
Potential Benefits
- Targeted Fat Loss: By activating AMPK, AICAR promotes lipid oxidation and reduces fat storage, making it a focal point for obesity research.
- Enhanced Endurance: Research demonstrates that AICAR significantly increases running endurance in sedentary mice by upregulating muscle gene expression (Narkar et al., 2008).
- Improved Insulin Sensitivity: Studies indicate that AICAR enhances glucose uptake in skeletal muscle independently of insulin, offering potential therapeutic pathways for type 2 diabetes.
- Mitochondrial Biogenesis: The compound stimulates the creation of new mitochondria, improving overall cellular energy capacity and metabolic health.
- Cardioprotection: Clinical trials have explored Acadesine for its ability to protect ischemic cardiac tissue during coronary artery bypass surgery.
Side Effects
Common side effects:
- Mild gastrointestinal distress or nausea
- Headaches and dizziness
- Temporary flushing or warmth at the injection site
- Changes in appetite
Rare or serious side effects:
- Hyperuricemia (elevated uric acid levels) leading to gout
- Cardiac arrhythmias or palpitations
- Significant alterations in blood glucose levels
- Kidney strain under high dosages
AICAR is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
AMPK Activation is the primary mechanism through which AICAR exerts its physiological effects. Upon entering the cell, AICAR is phosphorylated into ZMP, an analog of adenosine monophosphate (AMP). This accumulation of ZMP tricks the cell into sensing an energy deficit, directly binding to and activating AMP-activated protein kinase (AMPK) without altering the actual ATP/AMP ratio.
Metabolic Reprogramming follows this activation, shifting the cell from anabolic to catabolic processes. The activated AMPK pathway stimulates fatty acid oxidation, enhances glucose uptake via GLUT4 translocation, and triggers mitochondrial biogenesis through PGC-1alpha upregulation. Consequently, the body mimics the metabolic adaptations typically induced by rigorous cardiovascular exercise.
Origin & History
Early Discovery of AICAR dates back to the 1980s when it was initially investigated for its potential to preserve blood flow to the heart during surgery. Developed clinically under the name Acadesine, it reached Phase III clinical trials for ischemic heart disease, demonstrating its profound ability to modulate cellular energy under stress. However, its widespread fame emerged in 2008 when researchers at the Salk Institute published a landmark study revealing its capacity to enhance endurance in sedentary mice.
Regulatory Status for AICAR remains strictly limited to research and specific clinical investigations. While it is not approved by the FDA for general human use, its potent performance-enhancing properties led the World Anti-Doping Agency (WADA) to ban it in professional sports. Today, the AICAR peptide continues to be extensively studied in preclinical models for metabolic disorders, muscular dystrophy, and targeted fat loss.